Page last updated: 2024-09-03

gefitinib and artenimol

gefitinib has been researched along with artenimol in 4 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(artenimol)
Trials
(artenimol)
Recent Studies (post-2010) (artenimol)
5,2315662,91953048
5,2315662,9191,419279987
5,2315662,919707

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Das, D; Hong, J1
Cao, Y; Jiang, AY; Jiang, XF; Jin, H; Wang, H; Wu, Y1
Lai, XY; Shi, YM; Zhou, MM1
Kong, L; Li, Y; Liu, H; Liu, X; Wang, LL; Yuan, F; Zhang, L; Zhang, Y; Zuo, Z1

Reviews

1 review(s) available for gefitinib and artenimol

ArticleYear
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
    European journal of medicinal chemistry, 2019, May-15, Volume: 170

    Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2019

Other Studies

3 other study(ies) available for gefitinib and artenimol

ArticleYear
Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.
    Molecular medicine reports, 2017, Volume: 16, Issue:3

    Topics: Apoptosis; Artemisinins; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin B1; Down-Regulation; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Up-Regulation

2017
Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
    The Kaohsiung journal of medical sciences, 2023, Volume: 39, Issue:7

    Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Ferroptosis; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species

2023
Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
    European journal of medicinal chemistry, 2019, Nov-15, Volume: 182

    Topics: Animals; Antineoplastic Agents; Artemisinins; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Tumor Cells, Cultured

2019